CX1003

Kanitinib · Beijing Konruns Pharmaceutical Co., Ltd.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for CX1003, covering 2024-10-17 to 2024-10-17. Get the full timeline:

Most recent: Clinical Trial Update: A Phase 1 Study of CX1003 (Kanitinib) in Patients with Advanced Solid Tumors [Phase 1]